US2010010202A1PendingUtilityA1
Human antibodies derived from immunized xenomice
Est. expiryJan 12, 2010(expired)· nominal 20-yr term from priority
C12N 2800/206C07K 16/248C12N 2840/203C07K 2317/24A01K 2207/15A01K 2217/075A01K 2217/00C12N 15/87C07K 16/2854C12N 15/90A01K 2217/30C07K 16/241C07K 16/462C07K 16/22C07K 16/2812A01K 2217/05A01K 2267/01C07K 16/00C07K 16/1282A61K 38/00C12N 15/8509C07K 16/244C07K 16/2875C07K 2317/21
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.
Claims
exact text as granted — not AI-modified1 - 44 . (canceled)
45 . A human monoclonal antibody or an antigen binding portion thereof that specifically binds human TNF-α.
46 . The antibody or antigen binding portion thereof according to claim 45 , wherein said antibody comprises a kappa (K) immunoglobulin light chain.
47 . The antibody or antigen binding portion thereof according to claim 45 , wherein said antibody comprises an immunoglobulin heavy chain selected from the group consisting of a mu (μ) heavy chain and a gamma (γ) heavy chain.
48 . The antibody or antigen binding portion thereof according to claim 47 , wherein said antibody comprises a kappa (κ) immunoglobulin light chain.
49 . The antibody or antigen binding portion thereof according to claim 47 , wherein said antibody comprises a mu (μ) immunoglobulin heavy chain and a kappa (κ) immunoglobulin light chain.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.